Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
VIVITROL injection and VIVITROL Placebo Injection , 24 weeks
BRIGHT MINDS BIOSCIENCES INC.
Amphetamine Dependence
1 trial -
VP-102 - Cantharidin, Topical Film Forming Solution
Verrica Pharmaceuticals
Molluscum Contagiosum
2 trials -
VRDN (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor with half-life extension), TED SC Placebo
Viridian Pharma Ltd
Thyroid eye disease
1 trial -
VRDN (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor with half-life extension), TED SC Placebo
Viridian Pharma Ltd
Thyroid eye disease
1 trial -
VX-445/VX-661/VX-770 fixed-dose combination granules, VX-445/VX-661/VX-770 fixed-dose combination granules, Kalydeco 75 mg granules in sachet, Kalydeco 75 mg film-coated tablets, VX-770 75mg, VX-770 granules, Kaftrio 37.5 mg/25 mg/50 mg film-coated tablets, Kaftrio 75 mg/50 mg/100 mg film-coated tablets, Kalydeco 150 mg film-coated tablets
Vertex Pharmaceuticals (Australia) Pty.
Cystic Fibrosis
1 trial -
VX-445/VX-661/VX-770 fixed-dose combination granules, VX-770 75mg, VX-770 granules, Kaftrio 75 mg/50 mg/100 mg granules in sachet, Kalydeco 50 mg granules in sachet, VX-445/VX-661/VX-770 fixed-dose combination granules, Kaftrio 60 mg/40 mg/80 mg granules in sachet, VX-770 50mg, Kalydeco 59.5 mg granules in sachet, Kalydeco 25 mg granules in sachet, Kalydeco 75 mg granules in sachet, VX-445/VX-661/VX-770 granules, VX-445/VX-661/VX-770 granules, Ivacaftor 25 mg granules
Vertex Pharmaceuticals (Australia) Pty.
Cystic Fibrosis
1 trial -
VX-661 Plus Ivacaftor Combination
Vertex Pharmaceuticals (Australia) Pty.
Cystic Fibrosis
2 trials -
VX-770 granules, VX-445/VX-661/VX-770 fixed-dose combination granules, VX-445/VX-661/VX-770 granules, Kalydeco 25 mg granules in sachet, VX-445/VX-661/VX-770 granules, Kalydeco 50 mg granules in sachet
Vertex Pharmaceuticals (Australia) Pty.
Cystic Fibrosis
1 trial -
VX-880 solution for infusion
Vertex Pharmaceuticals (Australia) Pty.
Type 1 Diabetes Mellitus with Impaired Hypoglycemic Awareness and Severe Hypoglycemia
1 trial -
VYEPTI 100 mg concentrate for solution for infusion
H. Lundbeck A/S
Migraine
1 trial -
VYEPTI 100 mg concentrate for solution for infusion
H. Lundbeck A/S
Chronic migraine
1 trial -
VYEPTI 100 mg concentrate for solution for infusion, Nacl 0.9%
H. Lundbeck A/S
Migraine
1 trial -
Valbenazine
NEUROCRINE BIOSCIENCES INC
Chorea, Huntington
3 trials -
Valbenazine
NEUROCRINE BIOSCIENCES INC
Tardive Dyskinesia
2 trials -
Valbenazine, Valbenazine, Placebo for valbenazine capsules
NEUROCRINE BIOSCIENCES INC
Schizophrenia
1 trial -
Varenicline
BRIGHT MINDS BIOSCIENCES INC.
Nicotine Dependence
6 trials -
Varenicline
BRIGHT MINDS BIOSCIENCES INC.
Nicotine Addiction
1 trial -
Vatiquinone
PTC Therapeutics International Limited
Friedreich Ataxia
1 trial -
Vaxneuvance suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (15-valent, adsorbed), Pneumococcal Conjugate Vaccine (PCV)
Sanofi-aventis Healthcare Pty Ltd
Pneumococcal Immunization
1 trial -
Vectibix 20 mg/ml concentrate for solution for infusion
Fondazione Telethon ETS
Unresectable left sided RAS/B-RAF wild-type metastatic colorectal cancer
1 trial -
Vehicle cream (same formulation of cream as the test product but without active substance and the phosphoric acid), Ruxolitinib (INCB018424) cream
Incyte
Hidradenitis Suppurativa
1 trial -
Vehicle cream (same formulation of cream as the test product but without active substance), Ruxolitinib (INCB018424) cream
Incyte
Prurigo Nodularis
1 trial -
Vehicle cream: same formulation of cream as the test product but without active substance and phosphoric acid, Ruxolitinib (INCB018424) cream
Incyte
Atopic Dermatitis
1 trial -
Vehicle cream: same formulation of cream as the test product but without active substance., Ruxolitinib (INCB018424) cream
Incyte
Atopic Dermatitis
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources